Asfotase alfa (Strensiq) Managed Access Agreement for treating Hypophosphatasia
14th November 2022
On the 2nd August 2017, a Managed Access Agreement (MAA) was established, enabling patients living with Hypophosphatasia (HPP) that met the “start criteria” outlined in the MAA to access asfotase alfa. Towards the end of the MAA period, NICE reviewed all the patient data that has been collected and made the draft recommendation for use only in people with perinatal-/infantile-onset hypophosphatasia.
Read our historical HPP MAA documents: